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Chorea is a movement disorder which may be associated with immunologic diseases, in
particular in the presence of antiphospholipid antibodies (aPL). Choreic movements have
been linked to the isolated presence of plasmatic aPL, or to primary, or secondary antiphos-
pholipid syndrome. The highest incidence of aPL-related chorea is detected in children
and females. The presentation of chorea is usually subacute and the course monopha-
sic. Choreic movements can be focal, unilateral, or generalized. High plasmatic titers of
aPL in a choreic patient can suggest the diagnosis of aPL-related chorea; neuroimaging
investigation does not provide much additional diagnostic information. The most relevant
target of aPL is β2-glycoprotein I, probably responsible for the thrombotic manifestations of
antiphospholipid syndrome. Etiology of the movement disorder is not well understood but a
neurotoxic effect of aPL has been hypothesized, leading to impaired basal ganglia cell func-
tion and development of neuroinflammation. Patients affected by aPL-related chorea have
an increased risk of thrombosis and should receive antiplatelet or anticoagulant treatment.
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INTRODUCTION
As defined by Sanger, chorea is “an ongoing random-appearing
sequence of one or more discrete involuntary movements or move-
ment fragments. Movements appear random due to variability in
timing, duration, direction, or anatomic location. Each movement
may have a distinct start and end point, although these may be dif-
ficult to identify since movements are often strung together one
immediately following or overlapping with another” (Sanger et al.,
2010).
Chorea is a well-known but rare manifestation associated with
immune system dysfunction and, particularly, with the presence
of antiphospholipid antibodies (aPL).
The aPL represent a heterogeneous population of auto-
antibodies directed against phospholipid binding proteins, phos-
pholipids, and other proteins. The most relevant target of aPL is
β2-glycoprotein I (β2-GPI). Cardiolipin, prothrombin, annexin V,
protein C, protein S, and proteins from the kininogen system are
less common ligands. Less frequently, aPL are observed to bind to
phospholipid groups, such as phosphatidyl-serine, phosphatidyl-
ethanolamine, phosophatidyl-inositol (Arvieux et al., 1997).
Lupus anticoagulant (LAC) is a subclass of aPL, detected by
a prolongation of phospholipid-dependent in vitro coagulation
assays. High plasmatic titers of aPL are strongly associated with
hematologic, obstetric, neurologic, and cutaneous abnormalities.
The first description of aPL dates back to 1906, when these anti-
bodies were recognized for the false positivity in the Wassermann
test because of their ability to bind the phospholipids of bovine
heart extracts (Wassermann et al., 1906). Only in the early 1980s,
aPL were identified for their association with thrombosis (Harris
et al., 1983).
Low and non-pathogenic titers of aPL can be detected in 1–5%
of healthy people (Petri, 2000), higher levels of aPL are observed
in less than 2% of control subjects (Ginsberg et al., 1995). The
prevalence increases with advancing age, reaching highest rates in
elderly people with coexisting chronic diseases (Petri, 2000).
Genetic and environmental factors affect the appearance of
aPL and their clinical expression. A genetic predisposition has
been reported by HLA-linked association studies: HLA-DR4,
-DR7, -DRw53, and -DQB1∗0302 haplotypes have been cor-
related with aPL occurrence (Sebastiani et al., 2003). Infec-
tions or drug exposure can determine the emergence of aPL,
usually without clinical manifestations. The hepatitis C virus,
human immunodeficiency virus (HIV), human herpes virus,
adenovirus, and parvovirus B19 are the most common viral
infections related to aPL detection; aPL can be also detected
in bacterial diseases, such as leprosy and syphilis (Sène et al.,
2008). Procainamide, phenothiazines, quinine, oral contracep-
tives, and anti-TNF agents are the drugs that may induce gen-
eration of aPL (Ramos-Casals et al., 2008; Dlott and Roubey,
2012).
The presence of persistently high plasmatic levels of aPL, mainly
anticardiolipin (aCL), anti-β2-GPI, and LAC antibodies, repre-
sents the pathogenic basis of antiphospholipid syndrome (APS).
APS, also known as antiphospholipid antibody syndrome (APAS)
or Hughes’ syndrome, is a systemic autoimmune condition char-
acterized by a hypercoagulable state, responsible for arterial and
venous thrombosis, and pregnancy morbidities.
Antiphospholipid syndrome can be defined primary when it
elapses in the absence of any underlying autoimmune disorder
(PAPS), or secondary when associated with chronic inflammatory
conditions (SAPS; Miyakis et al., 2006). The classification retains
today only a nosologic role because there is no evidence of clini-
cal differences between these two conditions (Vianna et al., 1994;
Cervera et al., 2002).
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Systemic lupus erythematosus (SLE) is the most common cause
of SAPS (Cervera, 2008). The positivity of aPL in SLE patients
varies from 12 to 30% for aCL (Cervera et al., 1993; Merkel et al.,
1996) to 15–34% for LAC antibodies (Love and Santoro, 1990;
Cervera et al., 1993). Symptoms and signs of APS are present in
50–70% of SLE patients with aPL after a follow-up of 20 years
(Alarcon-Segovia et al., 1992; Petri, 2000). On the other hand, up
to 30% of SLE patients with aCL do not develop clinical throm-
botic events or pregnancy problems over an average follow-up of
7 years (Alarcon-Segovia et al., 1992). Transition from PAPS to
SLE-associated APS has been reported (Mujic et al., 1995) but it is
a relatively uncommon event (Mackworth-Young, 2006).
Immunologic conditions less frequently associated with aPL
are lupus-like syndrome, Sjögren’s syndrome, rheumatoid arthri-
tis, scleroderma, and systemic vasculitis (Ostrowski and Robinson,
2008).
Ischemic stroke, due to arterial thrombosis, represents the
most common neurological manifestation and the major cause
of morbidity and mortality in APS (Cervera et al., 2009). Several
neurological symptoms and movement disorders have been asso-
ciated with high titers of APL: migraine (20.2%), seizures (7%),
multi-infarct dementia (2.5%), chorea (1.3%), acute encephalopa-
thy (1.1%), transient amnesia (0.7%), cerebral venous thrombosis
(0.7%), cerebellar ataxia (0.7%), transverse myelopathy (0.4%),
hemiballismus (0.3%; Cervera et al., 2009). Isolated reports have
concerned parkinsonism-dystonia (Huang et al., 2008), paroxys-
mal dyskinesias (Engelen and Tijssen, 2005), tics (Seijo-Martinez
et al., 2008), and corticobasal degeneration-like syndrome (Morris
and Lees, 1999). Sneddon’s syndrome, characterized by ischemic
vascular disease and livedo reticularis, has also been associated
with aPL (Caldas and de Carvalho, 2011). Chorea represents the
most common movement disorder (1.3%; Cervera et al., 2009)
and constitutes one of 19 SLE related neuropsychiatric manifes-
tations established by the American College of Rheumatology in
1999 (The American College of Rheumatology, 1999).
In 1941 Zeller first described choreic movements as a clinical
presentation of SLE (Zeller, 1941) and, more than 30 years later,
Hughes related chorea to the presence of aPL in the first description
of APS (Hughes, 1984).
PATHOGENESIS
Anti-β2-GPI should be considered responsible for the thrombotic
manifestation of APS (Viard et al., 1992). Several sub-populations
of anti-β2-GPI, capable of binding different domains of β2-GPI,
are detectable (Shoenfeld et al., 2003). Only the antibodies directed
against the first domain of the protein are related to vascular
disorders occurring in APS (de Laat et al., 2009). High levels of
β2-GPI are present in plasma but its role is not well understood
(de Groot and Meijers, 2011). β2-GPI plays a protective function
through scavenging activity: it helps to remove lipopolysaccha-
rides (Agar et al., 2011), cellular debris, apoptotic microparticles,
and oxided LDL from circulation and to neutralize toxic molecules,
such as nitric oxide and superoxide radicals (Balasubramanian and
Schroit, 1998; Matsuura et al., 2009; Abdel-Monem et al., 2010;
Passam et al., 2011). β2-GPI seems also to contribute to hemo-
stasis regulation, interfering with von Willebrand factor (vWF)
activity, and reducing platelet aggregation (Hulstein et al., 2007).
Thrombosis represents the final result of different pathogenic
pathways; clot formation, coagulation cascade, endothelial func-
tion, and fibrinolysis are variously impaired in APS (Figure 1). The
role of aPL in vascular thrombosis has been widely demonstrated;
in the most explanatory experimental test, aPL extracted from
patients affected by APS and passively infused in rats caused vessel
occlusion of mesenteric microcirculation (Fischetti et al., 2005). In
experimental models, aPL can bind to endothelial cells,monocytes,
and platelets and promote transductional activities. Several recep-
tors, such as annexin A2 (Romay-Penabad et al., 2009), toll-like
receptor 2 and 4 (TLR2, TLR4; Pierangeli et al., 2007), apolipopro-
tein E receptor 2 (Romay-Penabad et al., 2011), and different
signaling pathways, such as molecular nuclear-factor-kB (NFkB;
Montiel-Manzano et al., 2007) and p38 mitogen-activated protein
kinase (MAPK; Vega-Ostertag et al., 2005), have been reported in
APS pathology.
Impairment of cerebral circulation was the historical hypothe-
sis used to explain chorea and other movement disorders in APS
syndrome. According to this theory, aPL can determine occlusion
of lenticulo-striate arteries and produce ischemia of basal ganglia.
Three lines of evidence currently are against this explanation.
Firstly, neuroimaging studies have rarely demonstrated ischemic
lesions of basal ganglia in patients affected by APS. Secondly,
clinical benefits of corticosteroids and other drugs capable of
suppressing the immune system support a flogistic/autoimmune
hypothesis rather than a vascular theory. Finally, a direct effect of
aPL on neuronal tissue is progressively emerging.
Neurological involvement in APS could actually be described as
a two-phase process. Initially, aPL could bind to brain endothelium
causing endothelial dysfunction (Abbott et al., 2003; Soltesz et al.,
2008), leading to microthrombosis and blood vessel inflammation.
This causes disruption of the blood-brain-barrier, extravasation of
neurotoxic cytokines, and serum proteins, including aPL and acti-
vated thrombin (Katzav et al., 2010). In the second phase, aPL
could produce direct neural damage. The ability of aPL to bind
to neural cell surface has been well-demonstrated. In experimen-
tal models, anti-β2-GPI antibodies bind to neuron and astrocyte
membranes (Caronti et al., 1998). aPL IgG have been seen to inter-
act with surface-antigens of neuronal cell lines with dopaminergic
characteristics (Dale et al., 2011). aPL could modulate neuronal
activity in patients affected by aPL-related neuropsychiatric syn-
dromes; these antibodies depolarize synaptic rat brain extracts
and may have similar effects in human nerve terminals (Chap-
man et al., 1999). They could particularly interfere with excitatory
pathways through NMDA glutamate receptor over-activation, as
demonstrated in rat cerebellar granule cells (Riccio et al., 1998).
It has already been proved that aPL can bind cerebral white mat-
ter. Immunogold electron microscopy techniques have shown that
monoclonal phosphatidylserine-reactive antibodies react strongly
with myelin, preferentially with the major dense line formed by the
cytoplasmic apposition of the oligodendrocyte plasma membrane
(Kent et al., 2000).
CLINICAL FEATURES
The Euro-Phospholipid Group analyzed the prevalence of the
most relevant clinical and immunological features in a total cohort
of 1000 APS patients, derived from 13 European countries; this
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FIGURE 1 | Pathogenic mechanisms of thrombosis in APS. aPL disrupt
the coagulation balance in many different ways. They bind directly to blood
clotting-proteins, such as prothrombin, protein C, protein S, impairing their
activity (Malia et al., 1990; Atsumi et al., 1998; Bertolaccini, 2012). aPL
reduce the inhibitory effects of protein C on the procoagulant factors Va
and VIIIa, inducing an acquired Activated Protein C Resistance (aAPCR).
Protein C dysfunction also prolongs Plasminogen Activator Inhibitor-1
(PAI-1) activity, contributing to fibrinolysis disorder (Urbanus and de Laat,
2010). aPL block the tissue Plasminogen activator (tPA) activity directly and
inhibit the ability of annexin 2 to potentiate tPA-mediated plasminogen
activation (Krone et al., 2010). aPL stimulate the extrinsic pathway of
coagulation through up-regulation of tissue factor (TF) mRNA
(Lambrianides et al., 2010). APL damage platelet aggregation process.
They increase platelet expression of glycoprotein IIb-IIIa (GP IIb-IIIa) and
synthesis of thromboxane A2 (TXA2; Robbins et al., 1998; Pierangeli et al.,
2008); aPL can also reduce the inhibitory activity of β2-GPI on von
Willebrand factor (vWF), promoting platelet aggregation (Hulstein et al.,
2007). In experimental models aPL generate a proinflammatory state,
increasing the secretion of cytokines, such as IL1 and IL6, and promoting
the expression of adhesion molecules, such as E-selectin, intracellular cell
adhesion molecules 1 (ICAM1), and vascular adhesion molecules 1
(VCAM1; Pierangeli et al., 2008).
large multicentre study reported a 1.3% prevalence of chorea
(Cervera et al., 2009). Chorea represents a typical onset manifesta-
tion of APS in childhood (Cervera et al., 2009), whereas it is most
often anticipated by thrombotic events or pregnancy morbidity in
adulthood.
The main demographic and clinical data of aPL-related chorea
come from three studies conducted on large cohorts (Cervera
et al., 1997; Orzechowski et al., 2008; Reiner et al., 2011).
Table 1 summarizes the most relevant data from these stud-
ies. In adulthood aPL-chorea starts early at an average age of
21 years (Cervera et al., 1997; Reiner et al., 2011), but twelve
female patients, 10 non-SLE, and two SLE, had a median onset
age of chorea of 44 and 33 years, respectively (Orzechowski et al.,
2008).
aPL-related chorea is more common in females, with a male-
female ratio from 1:2 to 1:24 (Cervera et al., 1997; Orzechowski
et al., 2008). Hormonal factors probably determine a higher inci-
dence; chorea presentation is often triggered in women by preg-
nancy or estroprogestinic therapy (Cervera et al., 1997; Reiner
et al., 2011).
It is impossible to say if choreic movements are more com-
mon in the condition of isolated aPL positivity than in primary
or secondary APS. In Cervera’s study, 58% of patients suffered
from defined SLE, 12% had lupus-like syndrome, and 30% were
affected by PAPS (Cervera et al., 1997). Among SLE patients,
1–3% of adults and 9% of children present choreic movements
(Meyer and Kahn, 2000; Joseph et al., 2007; Spinosa et al., 2007).
Chorea generally starts within the first year after the onset of SLE,
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Table 1 | Clinical, diagnostic, and radiologic data from studies about aPL-related chorea.
Reference Number of
patient (M/F)
Mean age at
onset (range)
Isolated aPL positivity*;
APS
Unilateral; bilateral
chorea at onset
Recidivant
forms
Ischemic signs of basal
ganglia at CT or MR scan
Cervera et al. (1997) 50 (2/48) 21.2 (6–77) 0; 50 (15 PAPS – 35 SAPS) 18; 21 (11 NR) 16/50 5/31
Orzechowski et al. (2008) 18 (6/12) 44® 14; 4 6; 12 6/18 1/18
Reiner et al. (2011) 32 (4/28) 20.6 (9–62) 20; 12 (1 PAPS – 11 SAPS) 15; 15 (2 NR) 8/32 3/31
* Also in the context of an immunological disease.
®Median age in 10 non-SLE female patients.
PAPS-SAPS, primary-secondary antiphospholipid syndrome; NR, non-reported.
and often precedes the clinical diagnosis (Asherson et al., 1987;
Baizabal-Carvallo et al., 2011).
Upon the first encounter with a patient, it may be difficult to
clinically distinguish choreic movements associated with aPL from
other secondary choreas or specific inherited diseases. As in other
hyperkinetic diseases, aPL-related chorea is usually worsened by
anxiety and psychological stress and subsides during sleep. In the
initial phase, patients attempt to disguise chorea by incorporating
it into a purposeful activity; as the disease worsens, the patient can
appear fidgety and clumsy.
The presentation of chorea is usually described as subacute,
with progressive onset within days or weeks (Orzechowski et al.,
2008). aPL-related chorea can involve all body parts; the head, as
well as upper and lower extremities can be affected by involun-
tary movements. Choreic disorder can be unilateral or bilateral:
unilateral presentation is common and symptoms often start on
one side and successively affect the other (Reiner et al., 2012).
aPL-related chorea can be segmental, multifocal, or generalized.
Among Orzechowski’s cohort, one patient had segmental choreic
movements, eight multifocal, and nine generalized (Orzechowski
et al., 2008). The severity is usually mild-moderate (Orzechowski
et al., 2008). Choreic movements often appear in a single episode
and regress spontaneously or through medication. Reiner et al.
(2011) calculated the average duration of chorea in their cohort to
be 7.44 weeks. Involuntary movements recur in 25–30% of cases
and pregnancy commonly favors their recurrence (Cervera et al.,
1997; Reiner et al., 2011).
At onset, aPL-related chorea is often associated with other neu-
rological manifestations, as cognitive impairment, ataxia, epilepsy,
psychiatric symptoms, migraine, and dystonia (Orzechowski et al.,
2008). Chorea has been related to an increased risk of mitral and
aortic valvulopathies, which have been reported in 69% of patients
with aPL positivity (Reiner et al., 2012).
NEUROIMAGING ASPECTS
Several neuroradiological investigations have confirmed the rar-
ity of the association between aPL-related choreic disorder and
ischemic pathology of basal ganglia. The percentage of patients
with aPL positivity who showed basal ganglia ischemic lesions at
cerebral CT, MRI, or both, varied between 6 and 16% in four differ-
ent studies (Cervera et al., 1997; Galanaud et al., 2000; Orzechowski
et al., 2008; Reiner et al., 2011).
An important contribution to the study of aPL-related chorea
comes from positron emission tomography (PET) analysis. Cere-
bral PET studies have revealed 18-FDG increased uptake in the
striatum, contralateral to the side with involuntary movements
(Furie et al., 1994; Wu et al., 2007). Increased FDG uptake may
delineate a flogistic state of basal ganglia and can be explained by
glucose uptake by infiltrated lymphocytes and resident microglial
cells.
DIAGNOSIS
There are currently no diagnostic criteria for aPL-related chorea.
The appearance of choreic movements in patients with isolated
aPL positivity, PAPS, or SAPS should suggest this condition.
Anamnestic data, such as no family history of movement dis-
orders and lack of previous streptococcal infections; a careful
clinical assessment with the exclusion of specific systemic, neuro-
logic, and psychiatric symptoms; and laboratoristic and neurora-
diologic exams may exclude other causes of chorea. aPL-related
chorea is common in children and it is important to exclude
other possible causes, such as Sydenham’s chorea, benign heredi-
tary chorea, DNA repair diseases (ataxia-telangiectasia, ataxia with
oculomotor apraxia type 1 and 2), Wilson’s disease, pantothenate
kinase-associated neurodegeneration (Walker, 2011).
According to the Sydney criteria revision (Miyakis et al., 2006),
to make a diagnosis of APS, the patient must present at least one
clinical manifestation of vascular thrombosis or unexplained preg-
nancy morbidity, and elevated levels of aPL in the plasma. Vascular
events include episodes of arterial, venous, or small-vessel throm-
bosis in any tissue or organ with radiological or histopathological
confirmation. Pregnancy morbidity includes at least one of the
following: three or more consecutive miscarriages before the 10th
gestation week; one or more premature births related to eclamp-
sia, severe preeclampsia, or placental insufficiency before 34 weeks;
one or more unexplained fetal losses at or beyond the tenth week
of gestation (Miyakis et al., 2006).
Antiphospholipid syndrome recent diagnostic criteria do not
consider neuropsychiatric manifestations, despite progressive
emerging evidence of a direct interaction of aPL on neural tissue.
In our opinion, association of chorea alone with aPL positivity
and exclusion of all other relevant causes of acquired or genetic
chorea, should suggest a diagnosis of possible APS. This condition
may be definable also as “pre APS” because it may anticipate the
appearance of thrombotic manifestations (Asherson, 2006; Reiner
et al., 2011).
Regarding the available serological assays, aCL and β2-GPI,
of both IgM and IgG class, are detected by enzyme-linked
immunosorbent assay (ELISA), LAC by phospholipid-dependent
clotting assay. International standards for LAC positivity include
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prolongation of aPL-dependent clotting assay, evidence of inhibi-
tion demonstrated by mixing studies, evidence of aPL dependence,
and a lack of specific inhibition of any coagulation factor (Wisløff
et al., 2002). To allow a diagnosis of APS, persistent aPL positivity
must be confirmed on two occasions with an interval of at least
12 weeks (Miyakis et al., 2006).
Although antibodies against β2-GPI are considered responsi-
ble of APS, anti-β2-GPI assay does not correlate with the clinical
manifestation of thrombosis and fetal loss (Urbanus et al., 2009).
Anti-β2-GPI consist in a heterogeneous group of antibodies, only
a few of which are responsible for tissue damage. When associated
with infections or drug exposure, these antibodies may have no
pathogenic role (Shoenfeld et al., 2003; Sène et al., 2008; Dlott and
Roubey, 2012). As a functional test, LAC is the most powerful pre-
dictor of pathology in APS (Galli et al., 2003). This finding is also
confirmed in patients affected by aPL-related chorea: the percent-
age of LAC positivity varies between 84 and 92% of cases (Cervera
et al., 1997; Reiner et al., 2011).
THERAPEUTIC ASPECTS
From a neurological standpoint, therapeutic targets in patients
affected by aPL-related chorea are the primary or secondary pre-
vention of ischemic accidents and the remission of movement
disorders.
There have been no clinic trials on the primary prevention of
ischemic stroke in APS; the use of antiplatelet therapy may be use-
ful in individuals with persistently high levels of aPL, especially
those with other cardiovascular risk factors (Ruffatti et al., 2011).
In individuals affected by recurrent arteriothrombotic events, ther-
apeutic management should include long-term warfarin treatment
(Pengo et al., 2012).
Many different therapeutic strategies have been developed for
the management of movement disorders associated with aPL.
Discontinuation of trigger treatments, such as estroprogestinic
therapy, and introduction of anticoagulant or antiplatelet agents
represent the first therapeutic step toward chorea remission. In the
case of failure, several drugs can be used. Traditional neuroleptics,
such as haloperidol (0.01–0.05 mg/kg/die), have proven effective
on neural circuits responsible for choreic disorder. This treatment
should not last more than 4–8 weeks to avoid the risk of irreversible
tardive dyskinesia. Atypical neuroleptics and xenazine could rep-
resent effective alternatives. Otherwise, the flogistic/autoimmune
etiology of the disorder justifies the recourse to drugs which sup-
press the immune system, especially steroids. The available studies
do not suggest the superiority of one drug over another, par-
ticularly because two or more drugs have often been associated.
Retrospective analysis on 30 patients showed approximately equal
efficacy for steroids and neuroleptics when added on to previ-
ous therapy (Reiner et al., 2011). In the absence of remission,
a multidrug treatment should be started; combination therapy
with haloperidol and steroids has often proven effective in cases
of monotherapy failure (Cervera et al., 1997). In addition to
symptomatic therapy with dopamine antagonists, the European
League Against Rheumatism (EULAR) recommends the combi-
nation of glucocorticoids and immunosuppressive agents (aza-
thioprine, cyclophosphamide) to control disease activity (Bertsias
et al., 2010).
Isolated case reports suggest the use of intravenous
immunoglobulins, plasmapheresis, and treatment with mono-
clonal antibodies (rituximab) as additional therapeutic options
for patients who do not respond to conventional drugs (Lazurova
et al., 2007; Tsagalis et al., 2010).
METHODS
The Medline database was searched, using the following terms,
both alone and in combinations: “antiphospholipid syndrome,”
“antiphospholipid antibody syndrome,” “Hughes’ syndrome,”
“APS,” “aCL antibodies,” “anti-β2-glycoprotein I antibodies,”
“LAC.” The terms were cross-linked with the neurological man-
ifestations of chorea, dyskinesia, hyperkinesias, and involuntary
movement. Available articles published in English, French, and
German between the years 1980 and 2012 were reviewed. Ref-
erences noted in relevant articles were also revised. Not all
publications accessed are addressed in the article.
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